In-vivo studies in mice demonstrated that rimonabant’s anxiogenic effects are driven by blockade of G protein signaling, whereas obesity-related insulin resistance is mediated by CB1R signaling through β-arrestin215. This evidence concerns the gene CNR1 and Insulin resistance.